Allergy & Immunology
Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.
28 Jun, 2021 | 10:01h | UTCCommentaries: Heterologous vaccine regimens against COVID-19 – The Lancet AND
Commentary on Twitter (thread – click for more)
NEW #COVID19 research—Phase 2 trial by @borobia_am, @antoniojcarcas
et al. reports BNT162b2 given as a 2nd dose in individuals prime vaccinated with ChAdOx1-S induced a robust immune response, with an acceptable and manageable reactogenicity profile. Read https://t.co/muL0XQxdjG. pic.twitter.com/BxPlXB8EF7— The Lancet (@TheLancet) June 26, 2021
RCT: Similar outcomes with mycophenolate mofetil vs. azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression.
29 Jun, 2021 | 09:50h | UTC
Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.
28 Jun, 2021 | 09:52h | UTCIs one vaccine dose enough if you’ve had COVID? What the science says – Nature
Commentary on Twitter
One vaccine dose for prior covid: @ElieDolgin reviews the recent data @Nature https://t.co/amJ4RcGtuW
Vaccination cards/proof should be modified here to equate prior covid as the 1st dose and not force people to get an unnecessary 2nd dose— Eric Topol (@EricTopol) June 27, 2021
[Preprint] Long Covid: Third of people infected have long term symptoms.
25 Jun, 2021 | 10:30h | UTCCovid-19: Third of people infected have long term symptoms – The BMJ
Original study (preprint): Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people – Imperial College London
Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.
25 Jun, 2021 | 10:33h | UTCOriginal Study: Long COVID in a prospective cohort of home-isolated patients – Nature Medicine
Commentary on Twitter
Analysis of a prospectively enrolled cohort of patients with #SARSCoV2 infections reveals a high proportion who experienced #LongCovid symptoms at 6 months, despite being relatively young and having only mild to moderate acute #COVID19 symptoms https://t.co/fuW2QpfJog
— Nature Medicine (@NatureMedicine) June 23, 2021
Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients can improve the immunogenicity of the vaccine.
24 Jun, 2021 | 10:32h | UTC
Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection.
24 Jun, 2021 | 10:38h | UTCPrimary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses – ACS Nano
Related: France recommends single dose of vaccine if previous Covid infection detected. AND [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. AND Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
Commentary on Twitter
Prior covid? Unless it's a severe case, one-dose mRNA vaccine adds considerable protection and nothing added by 2nd dose. This is now concordant w/ >20 studieshttps://t.co/8Qpuw193zk @acsnano pic.twitter.com/TJNbl8HPy9
— Eric Topol (@EricTopol) June 23, 2021
Report: SARS-CoV-2 variants and vaccines.
24 Jun, 2021 | 10:33h | UTCSARS-CoV-2 Variants and Vaccines – New England Journal of Medicine
Perspective | Delta variant triggers dangerous new phase in the pandemic.
24 Jun, 2021 | 10:43h | UTCDelta variant triggers dangerous new phase in the pandemic – Science
Interactive Infographic | Interpreting a lateral flow SARS-CoV-2 antigen test – “This calculator demonstrates how interpreting a covid-19 lateral flow device (LFD) result varies according to the pre-test probability, and the sensitivity and specificity of the LFD used”.
23 Jun, 2021 | 10:29h | UTCInterpreting a lateral flow SARS-CoV-2 antigen test – The BMJ
Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia.
23 Jun, 2021 | 10:25h | UTC
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach.
23 Jun, 2021 | 10:23h | UTC
National surveillance in England showed low risk of reinfection with Covid-19 – “There were 15,893 possible reinfections with SARS-CoV-2 identified up to 30 May 2021 in England throughout the pandemic, out of nearly 4 million people with confirmed infections. This is equivalent to around 0.4% cases becoming reinfected”.
21 Jun, 2021 | 08:56h | UTCNew national surveillance of possible COVID-19 reinfection, published by PHE – Public Health England
Related: Had COVID? You’ll probably make antibodies for a lifetime – Nature AND COVID-19 reinfection rate less than 1 percent for those with severe illness, study finds. AND Study shows low risk of SARS-CoV-2 reinfection 1 year after primary infection.
Concerned about the latest AstraZeneca news? These 3 graphics help you make sense of the risk – “Two people in Australia have died from thrombosis with thrombocytopenia after 3.8 million doses of the AstraZeneca vaccine delivered”.
21 Jun, 2021 | 08:48h | UTC
Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.
18 Jun, 2021 | 08:35h | UTCEditorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.
18 Jun, 2021 | 08:36h | UTCTreatment of Multisystem Inflammatory Syndrome in Children – New England Journal of Medicine
Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
Commentaries: Steroids may be effective treatment for COVID-19 complications in children – Imperial College London AND Expert reaction to study looking at treatments for COVID-19 complications in children – Science Media Centre
[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.
17 Jun, 2021 | 09:55h | UTCOriginal study (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv
Commentaries: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science AND Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP AND Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT AND Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre
Commentary on Twitter
RECOVERY Pre-print:
In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion:
– reduced mortality
– increased speed of discharge
– reduced progression to invasive mechanical ventilation or deathhttps://t.co/rpDk4eUhmm pic.twitter.com/wXegKcDZg8— Martin Landray (@MartinLandray) June 16, 2021
RCT: Tofacitinib reduced the risk of death or respiratory failure in patients hospitalized with Covid-19 pneumonia.
17 Jun, 2021 | 09:58h | UTCTofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine
Commentary on Twitter:
Patients who were hospitalized with #COVID19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group. #IDTwitter
— NEJM (@NEJM) June 16, 2021
Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:43h | UTCCommentary: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:45h | UTCMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination.
17 Jun, 2021 | 09:41h | UTCRelated: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”.
16 Jun, 2021 | 08:26h | UTCA long-term perspective on immunity to COVID – Nature
[Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant.
15 Jun, 2021 | 09:09h | UTCNews Release: Vaccines highly effective against hospitalisation from Delta variant – Public Health England
Preprint: Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant
Commentary on Twitter
NEWS — Our new analysis shows for the first time that two doses of the #COVID19 #vaccines are highly effective against hospitalisation from the #Delta (B.1.61.2) #variant.
Read more: https://t.co/6z67CW85Zw pic.twitter.com/oyRFghHpXw
— Public Health England (@PHE_uk) June 14, 2021
(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.
15 Jun, 2021 | 09:12h | UTCCommentaries: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases AND Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT AND Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science AND Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP AND What the Novavax vaccine means for the global fight against Covid-19 – Vox
Commentary on Twitter (thread – click for more)
Good news—Novavax protein-subunit vaccine phase 3 trial shown to to be 90.4% effective overall, 100% against moderate to severe disease. This is different type from mRNA and from AZ/J&J adenovirus vaccines, and different from inactivated types. #COVID19 https://t.co/ajoGhaOUu9
— Eric Feigl-Ding (@DrEricDing) June 14, 2021
Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.
15 Jun, 2021 | 08:59h | UTCCommentaries: For Transplant Recipients, Third Time May Be the Charm for Better COVID Vaccine Protection – Hopkins Medicine AND Extra COVID Vaccine May Help Protect Transplant Patients – Associated Press
Commentary on Twitter
Our report about 3rd vaccine doses in transplant patients is published! "It is encouraging that antibody titers increased after the 3rd dose in 1/3 of patients who had negative antibody titers and in all patients who had low-positive antibody titers"https://t.co/6XElwyIdAa
— Dorry Segev (@Dorry_Segev) June 14, 2021